To cite this paper use one of the standards below:
Lower respiratory tract infections (LRTIs) are a major concern for global public health and the fifth leading cause of death worldwide, accounting for approximately 2.5 million deaths annually. Pneumonia represents approximately 60% of LRTIs, and given the increasing prevalence of multidrug-resistant microorganisms, its treatment has become increasingly limited. In this context, antimicrobial photodynamic therapy (aPDT), also known as photodynamic inactivation (PDI), has emerged as a promising alternative strategy. PDI involves a photosensitizer (PS) that, upon activation by light at an appropriate wavelength, undergoes photophysical and photochemical processes that generate reactive oxygen species (ROS). These species can damage multiple cellular targets, resulting in nonspecific cellular damage and reducing the likelihood of resistance development. However, PDI efficacy can be hindered by biological barriers, such as lung surfactant (LS), which may interfere with PS–bacteria interactions. To overcome this limitation, indocyanine green (ICG) can be associated with Gantrez™ AN-139 to improve PS delivery and bacterial interaction. Therefore, this study investigated PDI against susceptible and resistant Streptococcus pneumoniae strains in the presence and absence of LS using ICG associated with Gantrez™ AN-139. After determining subinhibitory PDI doses, these parameters were employed in combination with antibiotics. The resistant strain exhibited a photoinactivation profile similar to that of the susceptible strain, while LS strongly inhibited PDI in both strains. Synergistic effects were observed regardless of the order of PDI and antibiotic administration. Successive PDI cycles resulted in fourfold and twofold reductions in the minimum inhibitory concentration (MIC) of clindamycin and amoxicillin, respectively. These findings reinforce the potential of PDI as an adjuvant strategy for pneumococcal infections and highlight the importance of optimizing combined therapies. To the best of our knowledge, this is the first study to evaluate the interaction between ICG-mediated PDI and antibiotic therapy against S. pneumoniae, providing new evidence for approaches aimed at enhancing antimicrobial efficacy against a major pathogen involved in pneumonia.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper